2025
Mathematical modeling suggests 14-3-3 proteins modulate RAF paradoxical activation
Mendiratta G, Abbott K, Li Y, Yu J, Carlip P, Tong M, Huang J, Shokhirev M, McFall T, Wahl G, Stites E. Mathematical modeling suggests 14-3-3 proteins modulate RAF paradoxical activation. PLOS Computational Biology 2025, 21: e1013297. PMID: 40749078, PMCID: PMC12407542, DOI: 10.1371/journal.pcbi.1013297.Peer-Reviewed Original ResearchResistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years
Margot N, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen L, Ling J, Singh R, Dvory-Sobol H, Ogbuagu O, Segal-Maurer S, Molina J, Rhee M, Callebaut C. Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years. The Journal Of Infectious Diseases 2025, 231: 1239-1245. PMID: 39873394, DOI: 10.1093/infdis/jiaf050.Peer-Reviewed Original ResearchOptimized background regimenHIV-1HIV-1 RNA <HIV-1 RNA suppressionTreatment-experienced peopleTandem liquid chromatography/mass spectrometryFirst-in-class inhibitorResistant to 2HIV-1 capsidBackground regimenTreatment-experiencedVirological failureLenacapavirRNA suppressionDrug classesDrug measurementsResistance assaysMonotherapyPWHLiquid chromatography/mass spectrometryTreatmentDrugResistance analysisResuppressionYears
2017
Drug Resistance Assays for Mycobacterium tuberculosis
Kurz S, Salfinger M. Drug Resistance Assays for Mycobacterium tuberculosis. 2017, 1359-1365. DOI: 10.1007/978-3-319-47266-9_33.Peer-Reviewed Original ResearchDetection of drug resistanceEpidemic of drug-resistant tuberculosisAgar proportion methodAntimicrobial susceptibility testingDrug-resistant tuberculosisDrug resistance assaysDetection of patientsDrug-resistant Mycobacterium tuberculosis strainsMycobacterium tuberculosis strainsMinimal inhibitory concentrationPharmacodynamic correlationsSusceptibility testingDrug resistanceLiquid medium systemsEffective treatmentTuberculosis strainsScreening testProportion methodGenotyping methodsResistance assaysBacteriological methodsInhibitory concentrationMycobacterium tuberculosisTuberculosisPatients
2001
Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther supportDevelopment and Application of a Genotypic AZT Resistance Assay
Kyriakides T, Heimer R. Development and Application of a Genotypic AZT Resistance Assay. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211-220. DOI: 10.1097/00126334-200111010-00002.Peer-Reviewed Original ResearchViral loadCD4 countAZT resistanceResistance indexResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentResistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityReaction assaysCountAssaysFurther supportIndexAntiretroviralsHIV
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply